Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.
The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:
- KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
- KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
- KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
- KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.
Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.
Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.
For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.
Kymera Therapeutics (NASDAQ: KYMR) has priced a $225 million public offering of common stock and pre-funded warrants. The company is selling 2,002,313 shares at $40.75 per share and pre-funded warrants for 3,519,159 shares at $40.7499 each. Kymera has granted underwriters a 30-day option to purchase up to 828,220 additional shares. The offering is expected to close on August 21, 2024.
Proceeds will be used to advance Kymera's pipeline of preclinical and clinical degrader programs, for working capital, and other corporate purposes. The company may also use funds for in-licensing, acquisitions, or investments in complementary businesses or technologies. Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel are acting as joint book-running managers for the offering.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focusing on targeted protein degradation, has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option for an additional $30 million in shares. Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel are acting as joint book-running managers. Kymera intends to use the proceeds to advance its pipeline of preclinical and clinical degrader programs, for working capital, and potentially for in-licensing or acquiring complementary businesses or technologies. The offering is subject to market conditions and is being made through a shelf registration statement filed with the SEC.
Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Sanofi plans to expand KT-474/SAR444656 Phase 2 trials in HS and AD.
2. STAT6 degrader program on track for Phase 1 initiation in H2 2024.
3. TYK2 degrader program set to initiate and complete Phase 1 in 2025.
4. KT-253 (MDM2) and KT-333 (STAT3) oncology degrader programs showed major responses in clinical trials.
5. $702 million cash position as of June 30, 2024, with runway into H1 2027.
6. Q2 2024 collaboration revenues: $25.7 million; R&D expenses: $59.2 million; G&A expenses: $17.4 million; Net loss: $42.1 million.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), has announced it will report its second quarter 2024 financial results on August 7, 2024. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results. Investors can access the call via phone or through a live webcast available on the company's website. A replay of the webcast will be archived for future reference. This announcement indicates Kymera's commitment to transparency and regular communication with investors regarding its financial performance and progress in developing new small molecule medicines using TPD technology.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD) therapies, will participate in a fireside chat at the UBS Virtual TPD Day.
The event is scheduled for July 15, 2024, at 1:00 p.m. ET. A live webcast of the presentation will be accessible on the company's website under the 'News and Events' section in the Investors area. An archived replay will be available post-event.
Kymera Therapeutics announced that Sanofi will expand the ongoing Phase 2 trials for KT-474 (SAR444656) in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) after an interim review of safety and efficacy data. The expansion aims to accelerate progress toward pivotal studies. CEO Nello Mainolfi highlighted KT-474's potential to address significant unmet needs in large markets. Further details on trial designs and updated timings will be provided as the expanded Phase 2 trials progress.
Kymera Therapeutics presented new clinical data from its ongoing Phase 1 trial of KT-333, a STAT3 degrader, at the EHA Annual Meeting. KT-333 showed promising results in treating various hematological malignancies, including complete responses in two Hodgkin's lymphoma patients. The trial enrolled 47 patients across seven dose levels, achieving up to 95% STAT3 degradation. Notably, KT-333 was well-tolerated, showing mostly minor side effects. The company plans to continue dose escalation and expects to release more data in the second half of 2024.
Kymera Therapeutics presented new clinical data from its ongoing Phase 1 trial of KT-253, an MDM2 degrader, at the ASCO Annual Meeting. Results showed initial clinical proof of concept with efficacy in patients with tumor types such as MCC and AML. KT-253 demonstrated target engagement and upregulation of p53 pathway biomarkers even at low doses. The compound was generally well tolerated without the hematologic adverse events seen with traditional MDM2 inhibitors. The trial continues with more data expected in the second half of 2024.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD), announced its participation in the Jefferies 2024 Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. The Jefferies conference will take place in New York on June 5 at 11:30 a.m. ET, while the Goldman Sachs event will be held in Miami on June 11 at 2:40 p.m. ET. Both events will feature live webcasts, accessible through Kymera's website, with replays available post-events.
Kymera Therapeutics announced new clinical data for KT-253, an MDM2 degrader, from its ongoing Phase 1 trial. The data will be presented at the ASCO Annual Meeting from May 31 to June 4, 2024.
The study includes 18 patients, indicating promising results in tumor response and a favorable safety profile. Partial and complete responses were observed in patients with Merkel cell carcinoma and acute myeloid leukemia, respectively. KT-253 was well-tolerated, with common adverse events being nausea, fatigue, and headache. Further data will be shared later this year.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
What is Kymera Therapeutics' main focus?
What is the Pegasus platform?
What are some key drugs in Kymera's pipeline?
What diseases is Kymera targeting?
What recent achievements has Kymera made?
How does Kymera's technology differ from conventional therapies?
Who are Kymera's partners?
Where is Kymera Therapeutics headquartered?
How is Kymera funded?
Where can I find more information about Kymera?
